**Table D-59. Evidence table for studies addressing management of PPH (Chauleur 2008a)**

| **Study**  **Description** | **Intervention** | **Inclusion/Exclusion**  **Criteria & Population** | **Outcomes** |
| --- | --- | --- | --- |
| Author:  Chauleur et al.,  200860  Country:  France  Enrollment period:  January 1999 to February 2004  Birth setting:  Hospital  Facility characteristics:  University  Funding: NR  Design:  Population-based case series | **Intervention:**  Analyze the relationship between severe PPH, its related blood-derived substitutive treatments and the occurrence of venous thromboembolism (VTE) in the following first six weeks post birth  **Groups:**  **G1:** Women during their first pregnancy  **G1a:** Subgroup of women who developed severe PPH  N at enrollment:  **G1:** 32,463  **G1a:** 317 (0.98%)  N at follow-up: NR  Duration of treatment: NR  Timing of treatment: NR  Order of treatment: 1 As soon as excessive bleeding was observed, manual explorations of the uterus and oxytocin injection were performed  2 Sulprostone was injected IV in the case of persistent hemorrhage: initial 500 ug dose was given over a one hour duration, then a second dose over three to five hours  3 Fluid therapy was used to obtain hemodynamic stability and normovolemia  4 Transfusion of packed RBC units was performed to maintain the hemoglobin level above 70 g/l-1  5 The practitioner in charge of the patient decided to inject 20 ml/kg-1 of fresh frozen plasma (FFP) in case of plasma factor V lower than 30% normal values and one unit of platelet (PLT) per 10 kg body weight in case of thrombocytopenia lower than 50 g/l-1  Length of follow-up: NR | **Operational definition of PPH:**  PPH was defines as uterine bleeding occurring in the first 24 hours after delivery, persisting after manual exploration of the uterine cavity and requiring I.V. prostaglandin administration.  Severe PPH was defined as peripartum decrease of hemoglobin >40 g/l-1 –the reference value taken into consideration was the last hemoglobin concentration before delivery-; or in case of transfusion of at least four packed red blood cell (RBC) units, of hemostatic intervention (surgical uterine sutures, artery litigation, artery embolization, hysterectomy) or of death.  **Definition of success of treatment**: NR  **Method of blood loss measurement:** NR  **Severity:** See above  Inclusion criteria:   * Women during their first intended pregnancy   Exclusion criteria:   * Previous occurrence of superficial or deep vein thrombosis (DVT) in the patient or in any first degree relative * Chronic treatment during pregnancy interfering with the hemostatic system, including low- or high- dose aspirin * Any missing data on pregnancy loss   **Maternal age, yrs, mean (range):**  **G1:** 29.2 (21-36)  **G1a:** 29 (22-36)  **Parity:** NR  **Weeks gestation, mean (range):**  **G1a:** 39 (22-41)  **Single pregnancy:** NR  **Multiple pregnancy, n (%):**  **G1:** 340 (1)  **G1a:** 6 (1.9)  **Race/ethnicity, n (%):**  European Caucasians  **G1:** 26,323 (81.1)  Northern Africa Caucasians  **G1:** 4,447 (13.7)  Africans  **G1:** 1,006 (3.1)  Asians  **G1:** 683 (2.1)  **BMI, Mean (range), kg/m-2**  **G1:** 24.3 (16.1-33.7)  **G1a:** 23.9 (19.1-30.3)  **Baseline hemoglobin:** NR  **Mode of birth, n, (%):**  Cesarean  **G1:** 6,957 (21.4)  **G1a:** 76 (24)  Vaginal delivery  **G1:** NR  **G1a:** 241 (76)  **Risk factors:** NR  **Primary etiology of PPH, n (%):**  Uterine atony  **G1a:** 199 (62.8)  Birth canal trauma  **G1a:** 29 (9.1)  Placenta accreta  **G1a:** 2 (0.6)  Placenta praevia, uterine inversion  **G1a:** 1 (0.3)  Placenta abruption, uterine atony  **G1a:** 23 (7.3)  Retained secondines  **G1a:** 20 (6.3)  Retained secondines, disseminated intravascular coagulation  **G1a:** 5 (1.6)  Retained secondines, uterine atony  **G1a:** 30 (9.5)  Retained secondines, uterine inversion 8  **G1a:** 8 (2.5) | **Transfusion, n (%):**  Red blood cells  **G1a:** 317 (100)  Platelets  **G1a:** 29 (9.1)  Fresh frozen plasma  **G1a:** 51 (16.1)  Fibrinogen concentrates  **G1a:** 29 (9.1)  **Harms, n:**  Lower limb DVT  **G1:** 11  Superficial vein thrombosis  **G1:** 60  **G1a:** 3  Venous thromboembolism  **G1a:** 0  **Mortality, n:**  **G1a:** 0  **Confounders:** NR  **Effect modifiers:** NR |